LIPO.OTC.PinkLipella Pharmaceuticals INC
10-Q: Lipella Pharmaceuticals Reports Q1 2025 Financial Results, Navigates Nasdaq Compliance
Sentiment:
Quarterly Report
Lipella Pharmaceuticals announces its Q1 2025 financial results, showing a net loss of $1.31 million and ongoing efforts to maintain Nasdaq compliance.
Capital raiseThe company entered into an At The Market Offering Agreement (the ATM Agreement) with H.C. Wainwright & Co., LLC (Wainwright) to sell shares of its Common Stock having an aggregate sales price of up to $2,641,881.Management of the Company may raise additional funds through the issuance of equity securities or debt.
Worse than expectedThe company's net loss increased from $1.19 million in Q1 2024 to $1.31 million in Q1 2025, indicating a worsening financial performance.Grant revenues decreased from $145,880 to $129,390 year-over-year, suggesting a decline in funding from grants.
Summary
- Lipella Pharmaceuticals reported a net loss of $1.31 million for the three months ended March 31, 2025, compared to a net loss of $1.19 million for the same period in 2024.
- Grant revenues decreased to $129,390 from $145,880 year-over-year.
- Research and development expenses increased to $993,475 from $842,600 year-over-year, primarily due to increased outside services for the LP-310 clinical trial.
- General and administrative expenses decreased to $463,736 from $520,926 year-over-year.
- Cash and cash equivalents totaled $4,225,012 as of March 31, 2025.
- The company believes its existing cash and cash equivalents will be sufficient to fund operations through the end of 2025.
- Lipella is working to regain compliance with Nasdaq listing requirements, including shareholder approval and voting rights requirements.
- The company is developing LP-10 for hemorrhagic cystitis and LP-310 for oral lichen planus, with LP-310 currently in a Phase 2a clinical trial.
- An At The Market Offering Agreement was entered into on April 4, 2025, to sell shares of common stock up to an aggregate sales price of $2,641,881.
- The company extended its lease for its headquarters on March 20, 2025, for five years beginning July 1, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While the company is facing financial challenges and Nasdaq compliance issues, it has taken steps to address these issues and continues to progress its clinical trials. The company's cash position is also relatively stable, providing some runway for future operations.
Positives
- Cash and cash equivalents increased to $4,225,012 as of March 31, 2025, providing a stronger financial position compared to previous periods.
- General and administrative expenses decreased by approximately $57,000, indicating improved cost management.
- The company believes its existing cash and cash equivalents will be sufficient to fund operations and capital expenses through the end of 2025.
- Progress continues on clinical trials for LP-310, with top line data from the first two dose cohorts selected for presentation at a medical meeting.
- The company has taken steps to address Nasdaq compliance issues, including providing updates to the Nasdaq hearing panel.
Negatives
- The company reported a net loss of $1.31 million for Q1 2025, an increase from the $1.19 million loss in Q1 2024.
- Grant revenues decreased from $145,880 to $129,390 year-over-year.
- The company is facing challenges in maintaining compliance with Nasdaq listing requirements, specifically regarding shareholder approval and voting rights.
- Research and development expenses increased, driven by outside services for the LP-310 clinical trial, indicating higher operational costs.
- The company has a history of operating losses and expects to continue incurring losses for the foreseeable future, raising concerns about long-term financial sustainability.
Risks
- The company's ability to continue as a going concern is dependent on obtaining additional capital, which is not assured.
- Failure to regain compliance with Nasdaq listing requirements could result in delisting of the common stock, making it more difficult to raise capital and negatively impacting the stock price.
- The company has not yet commercialized any products and does not expect to generate revenue from product sales for several years, if at all.
- Clinical trials may not be successful, and regulatory approvals may not be obtained for LP-10, LP-310, or other product candidates.
- The company's future funding requirements are uncertain and could increase significantly, depending on the progress of R&D activities and clinical trials.
Future Outlook
The company expects expenses to increase substantially in connection with ongoing R&D activities and clinical trials. Based on the current operating plan, existing cash and cash equivalents are believed to be sufficient to fund operations and capital expenses through the end of 2025. The company anticipates continuing to incur operating losses and negative operating cash flows for the foreseeable future.
Management Comments
- Management of the Company may raise additional funds through the issuance of equity securities or debt.
- Management believes that it regained compliance with the Stockholders Equity Requirement.
Industry Context
Lipella operates in the clinical-stage biotechnology sector, which is characterized by high risk and uncertainty. Companies in this sector often rely on proprietary formulations and drug delivery platforms to differentiate themselves. The focus on diseases with significant unmet needs, such as hemorrhagic cystitis and oral lichen planus, aligns with a strategy to potentially reduce the cost, time, and risk associated with obtaining marketing approval. The company's approach of reformulating existing generic drugs is a common strategy to expedite development and potentially secure patent protection.
Comparison to Industry Standards
- Lipella's approach of reformulating existing generic drugs is similar to companies like Recro Pharma, which focuses on developing improved versions of existing drugs.
- The company's focus on rare diseases and orphan drug designation is comparable to companies like BioMarin Pharmaceutical, which specializes in developing therapies for genetic diseases.
- The company's reliance on equity financing is typical for clinical-stage biotech companies, as seen with companies like CRISPR Therapeutics and Editas Medicine, which frequently raise capital to fund their R&D activities.
- The company's cash runway through the end of 2025 is a critical metric, and investors will likely compare this to other biotech companies of similar size and stage of development to assess the company's financial stability.
Stakeholder Impact
- Shareholders face the risk of stock delisting from Nasdaq, which could negatively impact the stock price and liquidity.
- Employees may be affected by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
- Customers (patients) may benefit from the development of new therapies for unmet medical needs, but the success of clinical trials and regulatory approvals is uncertain.
- Suppliers and creditors may face increased risk of non-payment if the company's financial situation deteriorates.
- The company's ability to raise additional capital may be affected by its Nasdaq compliance issues and financial performance.
Next Steps
- The company intends to submit a response to the May Letter as soon as possible before May 19, 2025.
- The trial is expected to be completed in the second quarter of 2025.
- The top line data from the first two dose cohorts of this trial has been selected for podium presentation at the 2025 American Association of Oral Medicine and European Association of Oral Medicine Joint Meeting that will be held in Las Vegas, NV on May 15, 2025.
- The company will continue to monitor and address Nasdaq compliance issues.
- The company will continue to advance its clinical trials for LP-10 and LP-310.
- The company will continue to advance the preclinical development of its other programs.
Key Dates
| Date | Description |
|---|---|
| 2005 | Company Inception |
| 2020-07-01 | Lease agreement beginning date for principal headquarters |
| 2022-09 | NIH awarded a grant of $673,000 |
| 2022-12-22 | Completed initial public offering |
| 2023-06 | NIH approved an additional year of funding under the 2022 NIH Grant, increasing the total funding provided under the 2022 NIH Grant to $1,353,000 |
| 2023-07-26 | Entered a second lease for additional space on the fourth floor of the same building |
| 2023-08-01 | Commencing date of the second lease for additional space on the fourth floor of the same building |
| 2023-11-11 | Received orphan drug designation from the FDA for LP-410 for oral GVHD |
| 2024-01-01 | Terminated the Fourth Floor Lease early at no penalty upon mutual agreement with the landlord and replaced it with a lease of additional space that had become available immediately adjacent to our existing offices |
| 2024-03-05 | Received investigational new drug approval from the FDA for LP-410s treatment of oral GVHD |
| 2024-04-17 | Received a written notification from the Nasdaq Listing Qualifications staff notifying the Company that, based upon the closing bid price of the Common Stock for the last 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share of its Common Stock |
| 2024-08-21 | Received a letter from the Staff stating that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on Nasdaq to maintain a minimum of $2,500,000 in stockholders equity for continued listing |
| 2024-10-16 | The Staff notified the Company that it would delist the Common Stock from Nasdaq |
| 2024-11-08 | The Company enacted a 1-for-8 reverse stock split, in order to regain compliance with the minimum bid price requirement |
| 2024-12-05 | The Company and Spartan Capital Securities, LLC (Spartan) entered into that certain (i) placement agent agreement, dated December 5, 2024, as amended by that certain amendment to consulting agreement and placement agent agreement, made as of December 10, 2024, between the Company and Spartan (the Amendment), as further amended by that certain second amendment to placement agent agreement, dated February 23, 2025, by and between the Company and Spartan and (ii) consulting agreement and advisory agreement, made as of December 5, 2024, as amended by the Amendment, as further amended by that certain second amendment to consulting agreement and advisory agreement, dated February 28, 2025, by and between the Company and Spartan (collectively, the Spartan Agreements), pursuant to which Spartan agreed to provide placement agent and consulting services in connection with the Offering. |
| 2024-12-12 | The Nasdaq hearing was held |
| 2024-12-20 | The Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock (the Series B Certificate of Designation), authorizing 144,000 shares of Series B non-voting convertible preferred stock, par value $ 0.0001 per share, of the Company (the Series B Preferred Stock) and establishing the rights, preferences, privileges, qualifications, restrictions, and limitations of the Series B Preferred Stock, became effective upon the Companys filing with the Secretary of State of the State of Delaware (the Delaware Secretary of State) of the Series B Certificate of Designation and a Certificate of Correction to the Series B Certificate of Designation on such date (the Certificate of Correction), which corrected the effective date of the Series B Certificate of Designation to December 20, 2024. |
| 2024-12-23 | The Company filed the Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the Series C Certificate of Designation), with the Delaware Secretary of State, authorizing 1,050,000 shares of the Companys Series C voting convertible preferred stock, par value $0.0001 per share (the Series C Preferred Stock), establishing the rights, preferences, privileges, qualifications, restrictions, and limitations relating to the Series C Preferred Stock. |
| 2025-01-10 | Received a decision from the Panel granting the Companys request for continued listing on Nasdaq, subject to the Company demonstrating compliance with the Stockholders Equity Requirement |
| 2025-01-23 | We issued 64,702 shares of Common Stock upon the cashless exercise of 97,216 Placement Agent Warrants |
| 2025-03-17 | The Company issued warrants (the Warrants) to purchase up to 72,000 shares of Series B Preferred Stock at a price per Warrant equal to $0.125 in order to comply with applicable Nasdaq rules, with each Warrant exercisable for shares of Series B Preferred Stock at $100 per share, and such shares of Series B Preferred Stock convertible into shares of Common Stock at a conversion price equal to $2.16 per share, which was the Minimum Price of the Common Stock immediately prior to the execution of the subscription agreements for the purchase and sale of such Warrants (the Subsequent Offering). |
| 2025-03-20 | We notified Bridgeway Capital of our intent to renew our Leases for our headquarters at the end of their existing term, on June 30, 2025 |
| 2025-03-31 | End of Q1 2025 |
| 2025-04-04 | Entered into an At The Market Offering Agreement (the ATM Agreement) with H.C. Wainwright & Co., LLC (Wainwright) to sell shares of its Common Stock having an aggregate sales price of up to $2,641,881 |
| 2025-04-07 | 35,330 shares of Series B Preferred Stock were converted into 1,209,767 shares of Common Stock, and 260,185 shares of Series C Preferred Stock were converted into 260,185 shares of Common Stock |
| 2025-04-08 | Filed a Certificate of Amendment of Certificate of Designation of Preferences, Rights and Limitations of Series C Voting Convertible Preferred Stock (the Series C Certificate of Amendment) with the Secretary of State of the State of Delaware |
| 2025-04-14 | The Company provided the Panel with such an update. Additionally, as previously disclosed in the Current Report on Form 8-K filed by the Company with the SEC on April 14, 2025, the Company believes that it regained compliance with the Stockholders Equity Requirement, as of the date of this Form 10-Q the Company believes it remains in compliance with the Stockholders Equity Requirement. |
| 2025-05-12 | Received a written notification (the May Letter) from the Staff notifying the Company that the Staff determined that the Company failed to comply with Nasdaqs shareholder approval and voting rights requirements in connection with certain securities issued in connection with the Offering and the Subsequent Offering. |
| 2025-05-15 | The top line data from the first two dose cohorts of this trial has been selected for podium presentation at the 2025 American Association of Oral Medicine and European Association of Oral Medicine Joint Meeting that will be held in Las Vegas, NV |
| 2025-05-19 | The May Letter provides that the Company should present its views to the Panel with respect to these matters to the Panel in writing no later than May 19, 2025, and the Company intends to submit a response to the May Letter as soon as possible before such date. |
| 2025-06-30 | The Lease term expires |
| 2025-07-01 | Lease extension beginning date |
| 2025 | Trial is expected to be completed in the second quarter |
Keywords
Lipella Pharmaceuticals, financial results, Q1 2025, Nasdaq compliance, LP-10, LP-310, clinical trials, biotechnology, pharmaceuticals, going concern, capital raise
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.